anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a peptide including an amino acid sequence represented by general formula, X1-Leu-X2-Glu-X3-Glu-X4, and showing a proliferation activity of fibroblasts and keratinocyte constituting skin, and to a use of the same. In general formula, X_1 is Met, Ile, Phe, His, Lys, Arg, Glu, or Ile. X_2 is Lys ,Arg, His,, or Asn. X_3 is Trp ,Gly His, Tyr, or Arg. X_4 is Leu ,Asp, Asn, or Phe. Compared to a natural-type EGF, a skin cell proliferating peptide of the present invention has an identical skin cell proliferating ability and has a low molecular weight, thereby having very excellent skin transmittance. Accordingly, a composition including the peptide according to the present invention exhibits a very excellent effect in treating, preventing, or alleviating disease or states requiring an EGF activity, and can be applied to medical, quasi-drug, and cosmetic products.
The present application relates to cancer markers and methods of use thereof. The invention relates to a method and a composition for regulating synthesis of a glycosphingolipid of a ball series. In particular, the invention relates to glycozyme inhibitor compounds that modulate the synthesis of the glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway, compositions thereof, and methods of use; in particular, the carbohydrase inhibitors target α -4GalT in the synthetic pathway of the ball series; beta-4 GalNAcT-I; or a beta-3 GalT-V enzyme. In addition, the invention also relates to vaccines, antibodies and/or immunogenic conjugate compositions that target SSEA-3/SSEA-4/GLOBO H-associated epitopes (natural and modified) that induce the production of antibodies and/or binding fragments for use in modulating the synthesis of glycosphingolipids of the globular series. In addition, the invention also relates to methods of treating or detecting hyperproliferative diseases and/or conditions using the compositions described herein. In addition, the invention also relates to cancer stem cell biomarkers for diagnostic and therapeutic use.
Due to the involvement of various structures, patients with oral cancer may experience functional impairments after treatment, such as trismus, spinal accessory nerve dysfunction, neck dystonia, radiation fibrosis, and fatigue. This observational study aims to develop an AI-based system for tracking mandibular and shoulder movements using deep learning techniques. AI-generated pose estimations will be compared with gold standard measurements: maximal mouth opening will be compared with caliper measurements, and Therabilte scale, while shoulder abduction range of motion will be compared with universal goniometer measurements. We will recruit 20 healthy adults and 20 oral cancer patients. Data on maximal mouth opening and shoulder abduction will be collected through video recordings, calipers, Therabilte scale, and universal goniometers. The videos will be analyzed using deep learning to estimate mouth opening and shoulder abduction angles. These estimates will then be compared with the gold standard measurements. The Intraclass Correlation Coefficient (ICC), Mean Absolute Error (MAE), and Coefficient of Variation (CV) will be used as performance indicators to assess and compare the reliability, accuracy, and consistency of the models.
Locally recurrent nasopharyngeal carcinoma (NPC) presents substantial challenges in clinical management. Although postoperative re-irradiation (re-RT) has been acknowledged as a potential treatment option, standardized guidelines and consensus regarding the use of re-RT in this context are lacking. This article provides a comprehensive review and summary of international recommendations on postoperative management for potentially resectable locally recurrent NPC, with a special focus on postoperative re-RT. A thorough search was conducted to identify relevant studies on postoperative re-RT for locally recurrent NPC. Controversial issues, including resectability criteria, margin assessment, indications for postoperative re-RT, and the optimal dose and method of re-RT, were addressed through a Delphi consensus process. The consensus recommendations emphasize the need for a clearer and broader definition of resectability, highlighting the importance of achieving clear surgical margins, preferably through an en bloc approach with frozen section margin assessment. Furthermore, these guidelines suggest considering re-RT for patients with positive or close margins. Optimal postoperative re-RT doses typically range around 60 Gy, and hyperfractionation has shown promise in reducing toxicity. These guidelines aim to assist clinicians in making evidence-based decisions and improving patient outcomes in the management of potentially resectable locally recurrent NPC. By addressing key areas of controversy and providing recommendations on resectability, margin assessment, and re-RT parameters, these guidelines serve as a valuable resource for clinical experts involved in the treatment of locally recurrent NPC.
Sample collection occurred between August and November 2014. A total of 203 infants and their parents (101 at 6-7 m of age and 102 at 12-13 m of age) receiving care at the Moronacocha Health Center in Iquitos, Peru were recruited. All subjects were residents of Moronochocha, Iquitos, Loreto, outwardly healthy, and born at term with a birth weight of at least 2,500 g. Venous blood samples were collected by a lab technician at the local health center. Hemoglobin concentrations were immediately measured, and treatment given if warranted. Samples were subsequently transported to Selva Amazonica clinic, centrifuged, and serum was stored at -80 °C. Stool samples were collected by caregivers from diapers at home, taken to Selva Amazonica Clinic, and aliquoted. Fecal samples were analyzed for parasites at Selva Amazonica, and any necessary treatment was provided at the local health center. Serum and stool samples were shipped to UC Davis on dry ice, where they were stored at -80 °C until metabolomics and microbiome analyses. Serum aliquots were also shipped to the University of Hohenheim, Stuttgart, Germany for iron assessment, and measurement of inflammatory markers. All data integration and interpretation was performed at UC Davis.
Tele-dentistry is a method of providing oral healthcare and dental services through real-time transmission of clinical information using electronic medical records, digital imaging, photography, ICT, and the internet. Oral medicine is a dental specialty that uses tele-dentistry services to manage patients with systemic diseases and comorbidities. However, some oral disorders may have systemic consequences, necessitating additional diagnostic techniques and skilled doctors. Issues such as lack of oral medicine specialists, inexperienced community health workers, and inadequate training for managing complex oral conditions also pose challenges. Delayed diagnosis of oral cancers in underserved communities, poor patient management, high transportation costs, and lengthy waiting lists are some of the challenges faced by patients.

The COVID-19 pandemic has further complicated these issues, causing disruptions in educational programs and access to oral medicine services. Tele-dentistry can facilitate efficient communication between patients and healthcare professionals for various purposes. There is limited research on using tele-dentistry in oral medicine, especially for results like accuracy. Consequently, the present study is designed to evaluate the sensitivity and specificity of using mobile phone images versus conventional clinical examination as a screening tool for early detection of oral cancer.
Meta-analysis of post ACL reconstruction return to sport suggests that despite approximately 90% of patients achieving successful outcomes in terms of objectively measurable knee function, only 63% return to their pre-injury sport participation rate. This leads one to question what factors other than knee function may contribute to such a discrepancy. Prior studies have shown psychological factors, such as fear of re-injury, can play in role in whether a patient returns to play. However, the role of patient resilience on recovery is less clear. This research will examine the effect of patient resilience on post-ACLR return to sport. The Brief Resiliency Scale (BRS), a proven method of assessing ability to recover from stressful situations, will be used to evaluate patient resilience. The role of resilience on recovery post shoulder surgery, as well as rehabilitation in post-operative orthopaedic geriatric patients has been examined; however, the effect of resilience on specifically ACLR return to sport has yet to be studied.

This research will provide insight as to how to identify patients at high risk for not returning to sport, the first step in improving return to sport outcomes in ACL reconstruction patients.
For 6-weeks out of the 16-week randomized dietary crossover study, women will receive prepared frozen lunch and dinner meals as per the control schedule, but will be asked to consume daily meals, snacks, and calorie-containing beverages within an 8 to 10-hour period that fits their schedule. The meal plans will be individualized to meet weight maintenance energy requirements.
The randomized control trial will be conducted through convenient sampling. There will be two group the experimental group will receive functional task training. according to GMFS, Pediatric balance scale and goniometer to assess the gross motor function, ROM and balance in cerebral palsy, while control group will receive functional therapy program (bobath technique) to improve gross motor function, ROM and balance in cerebral palsy. The duration of the treatment will be 8 weeks. Gross motor function, pediatric balance scale, and goniometer will be used as outcome measure. Data will be analyzed on spss version 29, normality of the data will be checked and test will be applied according to the normality of the data either in will be parametric test or nonparametric based on the normality
A common problem in human vaccinology is the limited availability of efficient and non-toxic adjuvants capable of promoting mucosal responses. The potential usefulness of fibronectin-binding protein (SfbI) of  Streptococcus pyogenes  as immunological adjuvant was assessed using ovalbumin (OVA) as a model antigen. Mice were immunized by intranasal route either with soluble OVA or OVA covalently coupled to SfbI. Immunization with OVA-SfbI resulted in the elicitation of about 100-fold higher titres of anti-OVA serum IgG than using OVA alone. The anti-OVA IgG subclass pattern was dominated in both groups of mice by IgG1, followed by IgG2b, IgG2a, and IgG3. Immunization with OVA-SfbI also resulted in the elicitation of OVA-specific IgA in lung washes (24% of the total IgA), which was absent in mice immunized with OVA alone. Spleen cells from OVA-SfbI immunized mice also gave a much stronger proliferative response to in vitro restimulation with soluble OVA. Phenotypic analysis of proliferating cells showed an enrichment in CD4+ T cells, producing a pattern of cytokines (IL-4, IL-5, IL-6 and IL-10) characteristic of Th2-type cells. In contrast to immunization with soluble OVA alone, OVA-SfbI induced the generation of CD8+ OVA-specific cytotoxic cells. These results demonstrate that SfbI represents a promising mucosal adjuvant able to substantially improve cellular, humoral and mucosal responses, when coupled to an antigen administered by intranasal route.
PURPOSE: A composition for prevention and treatment of hepatitis C including ginsenoside Rg3 as an active ingredient is provided to be safe in the human body and to have less side effects as ginsenoside Rg3 shows remarkable anti-virus effects and antiapoptotic effects in HuH 7.5.1 cells infected with hepatitis C virus (HCV). CONSTITUTION: A composition for prevention and treatment of hepatitis C includes ginsenoside Rg3 or its pharmaceutically acceptable salt as an active ingredient. The ginsenoside Rg3 is represented by Chemical formula 1. The ginsenoside Rg3 is one separated from any one selected from the group consisting of ginseng, raw ginseng, white ginseng and red ginseng. A pharmaceutical composition is any one selected from the group consisting of tablet, pill, hard capsule, soft capsule, injection, liquid, suspension, syrup and granule. A health supplementary composition for prevention and alleviation of hepatitis C includes ginsenoside Rg3 or its pharmaceutically acceptable salt as an active ingredient.
Glioblastoma (GBM) is the most common malignant primary brain tumor, characterized by limited treatment options and a poor prognosis. Its aggressiveness is attributed not only to the uncontrolled proliferation and invasion of tumor cells but also to the complex interplay between these cells and the surrounding microenvironment. Within the tumor microenvironment, an intricate network of immune cells, stromal cells, and various signaling molecules creates a pro-inflammatory milieu that supports tumor growth and progression. Docosahexaenoic acid (DHA), an essential ω3 polyunsaturated fatty acid for brain function, is associated with anti-inflammatory and anticarcinogenic properties. Therefore, in this work, DHA liposomes were synthesized using a microfluidic platform to target and reduce the inflammatory environment of GBM. The liposomes were rapidly taken up by macrophages in a time-dependent manner without causing cytotoxicity. Moreover, DHA liposomes successfully downregulated the expression of inflammatory-associated genes (IL-6; IL-1β; TNFα; NF-κB, and STAT-1) and the secretion of key cytokines (IL-6 and TNFα) in stimulated macrophages and GBM cells. Conversely, no significant differences were observed in the expression of IL-10, an anti-inflammatory gene expressed in alternatively activated macrophages. Additionally, DHA liposomes were found to be more efficient in regulating the inflammatory profile of these cells compared with a free formulation of DHA. The nanomedicine platform established in this work opens new opportunities for developing liposomes incorporating DHA to target GBM and its inflammatory milieu.
The present invention relates to a pharmaceutical composition comprising an inhibitor of the expression or the activation of osteopontin protein as an active ingredient for treating cancer. Specifically, the osteopontin derived from cancer enables to increase EM through a CD44-mediated Erk1/2-MAPK signaling pathway. The increase in EM due to osteopontin directly influences the MDSC accumulation in a cancer environment. In addition, the growth of cancer and the EM is significantly inhibited in a mouse, when knock-downing (KD) the osteopontin to the cancer cell. Moreover, the composition is capable of inhibiting the growth of the cancer in the mouse by using an anti-osteopontin antibody, and exhibiting synergetic effects when being applied with immune cell-based vaccine. Therefore, the inhibitor of the expression or the activation of the osteopontin protein can be efficiently used as an active ingredient of an anticancer supplement agent and cancer treatment.
An aroma emission adlibitum paster which provides a drug absorption paper material as a central aroma storing layer with two sides thereof made of thermal sensitive glue coating film layer which provides avirulence, good high and low temperature resistance of initial viscosity. The outer two layers provide an anti-sticking paper layer which is coated with silicone in the inner side and printed with various patterns of flowers and birds on the outer part. The utility model can be printed with various patterns of flowers and birds on the surface. The aroma smell of plants that the utility model emits provides the effect of avoiding dirty things and dispelling evil as well as the effect of refresh oneself. The aroma emission adlibitum paster is not pasted on human skin, thus, the utility model is not easy to cause bad skin allergic reaction. The utility model provides very convenience using. The use of paper material for making the utility model does not pollute the environment due to that the utility model decomposes very fast after discarding.
SIGNIFICANCE STATEMENT: The renal lymphatic vasculature and the lymphatic endothelial cells that make up this network play important immunomodulatory roles during inflammation. How lymphatics respond to AKI may affect AKI outcomes. The authors used single-cell RNA sequencing to characterize mouse renal lymphatic endothelial cells in quiescent and cisplatin-injured kidneys. Lymphatic endothelial cell gene expression changes were confirmed in ischemia-reperfusion injury and in cultured lymphatic endothelial cells, validating renal lymphatic endothelial cells single-cell RNA sequencing data. This study is the first to describe renal lymphatic endothelial cell heterogeneity and uncovers molecular pathways demonstrating lymphatic endothelial cells regulate the local immune response to AKI. These findings provide insights into previously unidentified molecular pathways for lymphatic endothelial cells and roles that may serve as potential therapeutic targets in limiting the progression of AKI.
BACKGROUND: The inflammatory response to AKI likely dictates future kidney health. Lymphatic vessels are responsible for maintaining tissue homeostasis through transport and immunomodulatory roles. Owing to the relative sparsity of lymphatic endothelial cells in the kidney, past sequencing efforts have not characterized these cells and their response to AKI.
METHODS: Here, we characterized murine renal lymphatic endothelial cell subpopulations by single-cell RNA sequencing and investigated their changes in cisplatin AKI 72 hours postinjury. Data were processed using the Seurat package. We validated our findings by quantitative PCR in lymphatic endothelial cells isolated from both cisplatin-injured and ischemia-reperfusion injury, by immunofluorescence, and confirmation in in vitro human lymphatic endothelial cells.
RESULTS: We have identified renal lymphatic endothelial cells and their lymphatic vascular roles that have yet to be characterized in previous studies. We report unique gene changes mapped across control and cisplatin-injured conditions. After AKI, renal lymphatic endothelial cells alter genes involved in endothelial cell apoptosis and vasculogenic processes as well as immunoregulatory signaling and metabolism. Differences between injury models were also identified with renal lymphatic endothelial cells further demonstrating changed gene expression between cisplatin and ischemia-reperfusion injury models, indicating the renal lymphatic endothelial cell response is both specific to where they lie in the lymphatic vasculature and the kidney injury type.
CONCLUSIONS: In this study, we uncover lymphatic vessel structural features of captured populations and injury-induced genetic changes. We further determine that lymphatic endothelial cell gene expression is altered between injury models. How lymphatic endothelial cells respond to AKI may therefore be key in regulating future kidney disease progression.
BACKGROUND: Individuals with diabetes exhibit a higher risk of cardiovascular disease and mortality compared to healthy individuals. Following a transient ischemic attack (TIA) the risk of stroke and death increase further. Physical activity engagement after a TIA is an effective way of secondary prevention. However, there's a lack of research on how individuals with diabetes modify physical activity levels and how these adjustments impact survival post-TIA. This study aimed to determine the extent to which individuals with diabetes alter their physical activity levels following a TIA and to assess the impact of these changes on mortality.
METHODS: This was a nationwide longitudinal study, employing data from national registers in Sweden spanning from 01/01/2003 to 31/12/2019. Data were collected 2 years retro- and prospectively of TIA occurrence, in individuals with diabetes. Individuals were grouped based on decreasing, remaining, or increasing physical activity levels after the TIA. Cox proportional hazards models were fitted to evaluate the adjusted relationship between change in physical activity and all-cause, cardiovascular, and non-cardiovascular mortality.
RESULTS: The final study sample consisted of 4.219 individuals (mean age 72.9 years, 59.4% males). Among them, 35.8% decreased, 37.5% kept steady, and 26.8% increased their physical activity after the TIA. A subsequent stroke occurred in 6.7%, 6.4%, and 6.1% of individuals, while death occurred in 6.3%, 7.3%, and 3.7% of individuals, respectively. In adjusted analyses, participants who increased their physical activity had a 45% lower risk for all-cause mortality and a 68% lower risk for cardiovascular mortality, compared to those who decreased their physical activity.
CONCLUSIONS: Positive change in physical activity following a ΤΙΑ was associated with a reduced risk of mortality. Increased engagement in physical activity should be promoted after TIA, thereby actively supporting individuals with diabetes in achieving improved health outcomes.
For the Motivational Interviewing (MI) treatment group, a clinical public health nursing doctoral student trained in Motivational Interviewing administered six motivational interviewing therapy sessions, each 30 minutes long. A 3-month follow-up will then be applied.
All patients fulfilling inclusion criteria in intensive care settings in involved ICUs in Czech Republic will be included into the study. Data will be recorded for 1 consequent month. Basic demography will be evaluated. In each patient standard delirium screening based on the institutional ICU rules will be performed. If no screening method were set,Confusion Assessment Method - CAM-ICU for adult and pediatric Confusion Assessment Method -pCAM-ICU for pediatric patients would be used together with delirium management, restrain procedures, sedative/neuroleptics administration, 28-days mortality. All data will be recorded into to predefined eCRF.
This is a double-blind (neither physician or volunteer knows the name of the assigned study drug), placebo controlled (substance containing no medication), study in healthy, overweight or obese adult male volunteers. For each volunteer, the study consists of a screening phase (up to 30 days), a treatment phase during which volunteers will receive 4 study treatments in a randomized (study sequence assigned by chance) sequence (28 days), and a follow-up phase (10 days). During the treatment phase there will be at least 7 days between each of the 4 treatments. The four treatments will be JNJ-38431055, sitagliptin, JNJ-38431055 and sitagliptin, and placebo. The following safety evaluations will be taken throughout the study: Electrocardiogram (an ECG is a painless procedure that gives a picture of the electrical activity of the heart), blood pressure, heart rate, and blood samples for laboratory tests. The primary outcome will be the effect of JNJ-38431055 and sitagliptin on glucagon like peptide-1 (GLP-1) levels. Study drug will be administered as single oral doses separated by at least 7 days. The four treatments will be JNJ-38431055, sitagliptin, JNJ-38431055 and sitagliptin, and placebo.
Crohn's disease (CD) is a chronic inflammatory disease that leads to intestinal stricture in nearly 35% of cases within 10 years of initial diagnosis. The unknown pathogenesis, lack of universally accepted criteria, and absence of an effective management approach remain unconquered challenges in structuring CD. The pathogenesis of stricturing CD involves intricate interactions between factors such as immune cell dysbiosis, fibroblast activation, and microecology imbalance. New techniques such as single-cell sequencing provide a fresh perspective. Non-invasive diagnostic tools such as serum biomarkers and novel cross-sectional imaging techniques offer a precise understanding of intestinal fibrostenosis. Here, we provide a timely and comprehensive review of the worthy advancements in intestinal strictures in 2023, aiming to dispense cutting-edge information regarding fibrosis and to build a cornerstone for researchers and clinicians to make greater progress in the field of intestinal strictures.